Urticaria is hives. Anaphylaxis is a systemic, potentially life-threatening reaction. The distinction determines whether epinephrine is the next step — and delay in giving epinephrine for true anaphylaxis increases the risk of fatal outcome.
CLINICAL PRINTABLE
Coming Soon.
Coming Soon. A one-page Urticaria vs Anaphylaxis clinical reference is on the way.
1 · Recognition
- Urticaria (hives): transient, pruritic wheals (raised, erythematous, edematous plaques) that typically resolve within 24 hours without leaving a mark. Individual lesions are migratory. Angioedema (deeper swelling of dermis/subcutaneous tissue) frequently accompanies urticaria.
- Anaphylaxis diagnostic criteria (any one of three): (1) Acute onset with skin/mucosal involvement PLUS respiratory compromise or cardiovascular compromise; (2) Two or more of the following after exposure to a likely allergen: skin/mucosal symptoms, respiratory compromise, cardiovascular compromise, persistent GI symptoms; (3) Cardiovascular compromise alone after exposure to a known allergen.
- Hives alone — without respiratory, cardiovascular, or significant GI involvement — do not meet criteria for anaphylaxis. Epinephrine is not indicated for isolated urticaria.
- Common anaphylaxis triggers: foods (peanuts, tree nuts, shellfish, fish, milk, eggs), medications (beta-lactam antibiotics, NSAIDs, aspirin), insect stings (Hymenoptera), latex, exercise, idiopathic.
- Biphasic anaphylaxis: recurrence of anaphylaxis symptoms 1–72 hours after the initial reaction, without re-exposure to the trigger. Occurs in approximately 5–20% of cases. Justifies extended observation (4–6 hours minimum after epinephrine administration).
2 · Differential / Common Traps
- Giving antihistamines instead of epinephrine for anaphylaxis: antihistamines treat pruritus and urticaria but do not reverse airway edema, bronchospasm, or cardiovascular collapse. Epinephrine is the only first-line treatment for anaphylaxis.
- Delaying epinephrine because the patient 'only has hives': if anaphylaxis criteria are met, epinephrine should be given immediately. Delay increases the risk of fatal outcome. Epinephrine is safe — the risk of not giving it far exceeds the risk of giving it.
- Missing cardiovascular anaphylaxis without skin findings: approximately 10–20% of anaphylaxis cases present without urticaria or angioedema. Sudden hypotension or cardiovascular collapse after allergen exposure is anaphylaxis until proven otherwise.
- Confusing hereditary angioedema (HAE) with allergic angioedema: HAE presents with recurrent angioedema without urticaria, does not respond to epinephrine or antihistamines, and requires C1-esterase inhibitor concentrate, icatibant, or ecallantide for acute treatment.
- Discharging after a single dose of epinephrine without adequate observation: biphasic reactions occur in up to 20% of cases. Minimum 4–6 hours of observation after epinephrine administration is standard. High-risk patients (severe initial reaction, asthma, unknown trigger) warrant longer observation or admission.
3 · Workup and Interpretation
- Anaphylaxis is a clinical diagnosis — do not delay treatment for laboratory confirmation. Serum tryptase (drawn within 1–3 hours of symptom onset) can support the diagnosis retrospectively but is not required for acute management.
- For chronic urticaria (>6 weeks): CBC, CMP, thyroid function, and consideration of autoimmune workup. Most chronic urticaria is idiopathic (chronic spontaneous urticaria).
- Allergy referral after anaphylaxis: skin prick testing and specific IgE testing to identify the trigger. Venom immunotherapy for insect sting anaphylaxis. Prescription of epinephrine autoinjector and anaphylaxis action plan.
- C4 level (screening for HAE): low C4 between attacks is a sensitive screening test for hereditary angioedema. C1-esterase inhibitor level and function confirm the diagnosis.
4 · Treatment / Management
Anaphylaxis — immediate
Epinephrine 0.3–0.5 mg IM (anterolateral thigh) immediately. Supine position with legs elevated (unless respiratory distress). IV access, supplemental oxygen. Call for emergency assistance. Repeat epinephrine every 5–15 minutes if no improvement.
Anaphylaxis — adjunctive
Antihistamines (H1 and H2 blockers) for urticaria and pruritus — adjunctive only, not first-line. Systemic corticosteroids to reduce biphasic reaction risk — adjunctive only. IV fluids for hypotension. Bronchodilators for bronchospasm. Glucagon for patients on beta-blockers (blunts epinephrine response).
Urticaria — acute
Antihistamines (H1 blockers — cetirizine, loratadine, fexofenadine) are first-line. H2 blockers (famotidine) as adjunct. Short course of systemic corticosteroids for severe or refractory urticaria. Identify and eliminate the trigger when possible.
Chronic urticaria
Non-sedating H1 antihistamines (cetirizine, loratadine) at standard or up-titrated doses. Omalizumab (anti-IgE) for antihistamine-refractory chronic spontaneous urticaria. Avoid known triggers. Dermatology or allergy referral for refractory cases.
Discharge after anaphylaxis
Prescribe epinephrine autoinjector (two devices). Provide written anaphylaxis action plan. Educate on trigger avoidance. Arrange allergy referral. Prescribe antihistamines and short course of corticosteroids. Advise on biphasic reaction risk and when to return.
5 · Expected Course / Reassessment
- Acute urticaria (< 6 weeks) typically resolves spontaneously or with antihistamine treatment. Most cases are triggered by infection, medication, or food and resolve when the trigger resolves.
- Chronic urticaria (> 6 weeks) is most commonly idiopathic (chronic spontaneous urticaria). It can persist for months to years. Omalizumab has significantly improved outcomes for antihistamine-refractory cases.
- Anaphylaxis: most patients recover fully with prompt epinephrine treatment. Biphasic reactions can occur — individualize observation based on severity, treatment response, risk factors, and access to emergency care.
- Recurrent anaphylaxis risk is reduced by trigger avoidance, venom immunotherapy (for insect sting allergy), and carrying an epinephrine autoinjector.
6 · Escalation
- Anaphylaxis not responding to initial epinephrine — repeat epinephrine, IV fluids, consider epinephrine infusion, ICU transfer.
- Airway compromise (stridor, hoarseness, drooling) — prepare for advanced airway management. Anesthesia/ENT involvement may be needed for severe angioedema.
- Refractory hypotension — IV epinephrine infusion, vasopressors, aggressive fluid resuscitation.
- Suspected HAE not responding to epinephrine/antihistamines — C1-esterase inhibitor concentrate, icatibant, or ecallantide. Hematology/allergy consultation.
Apply It · Patient Cases
CASE 1
A 24-year-old presents with widespread hives after eating shrimp. She has pruritus and urticaria on the trunk and arms. No throat tightness, no shortness of breath, no hypotension, no GI symptoms. Isolated urticaria — anaphylaxis criteria are not met. Cetirizine is given. She is observed for 1 hour and discharged with antihistamines and allergy referral.
CASE 2
A 31-year-old develops hives, throat tightness, and wheezing 10 minutes after a bee sting. Anaphylaxis criteria are met (skin involvement + respiratory compromise). Epinephrine 0.3 mg IM is given immediately. She improves within minutes. She is observed for 6 hours, prescribed an epinephrine autoinjector, and referred to allergy for venom immunotherapy.
NOW CHANGE ONE DETAIL
Same patient as Case 2, but she is on metoprolol for hypertension. Her response to epinephrine is blunted. Glucagon 1–2 mg IV is added to overcome the beta-blocker effect. Higher doses of epinephrine may be required. This is a recognized complication of anaphylaxis in beta-blocker users.
Bottom Line
Hives alone are not anaphylaxis. Anaphylaxis requires multi-system involvement or cardiovascular compromise. When anaphylaxis criteria are met, epinephrine IM is the only first-line treatment — antihistamines are adjunctive.
EVIDENCE & REFERENCES
- Sampson HA, et al. Second symposium on the definition and management of anaphylaxis. J Allergy Clin Immunol. 2006;117(2):391–397. doi:10.1016/j.jaci.2005.12.1303
- Simons FE, et al. World Allergy Organization anaphylaxis guidelines. World Allergy Organ J. 2011;4(2):13–37. doi:10.1097/WOX.0b013e318211496c
- Zuberbier T, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. doi:10.1111/all.13397